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Abstract
Since the Nobel Prize in Physiology or Medicine 1976 Baruch Blumberg and Irving 
Millman developed the first prophylactic plasma-derived hepatitis B vaccine - also 
considered the world´s first cancer vaccine- so much progress has been made in 
the development of new immunogenic and safe vaccines. However, improvements 
are still clearly required since vaccines currently available in the market produce 
mainly a humoral immune response, require cold storage, a three dose schedule, 
the costs of the vaccines are high, many developing or low-incoming countries 
display a poor compliance in vaccination programs, and 5-10% of the vaccinated 
individuals are poor or non-responders.
To overcome such drawbacks, nanotechnology has emerged as a new platform for 
vaccine development. Nanocarrier-based delivery systems offer an opportunity 
to stimulate both humoral as well as cell-mediated responses and to induce 
mucosal and systemic immunity simultaneously. Furthermore, nanocarrier-based 
delivery systems avoid the need for sterile needles. This manuscript reviews 
the current knowledges on the vailable hepatitis B vaccines and introduces the 
recent advances in nanocarrier-based hepatitis B vaccine delivery systems. The 
challenges in the development of needle-free nanotechnologies are also discussed. 
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systems; Needle-free nanotechnologies
Submit Manuscript | http://medcraveonline.com Int J Vaccines Vaccin 2015, 1(2): 00007
Abbreviations: CHB: Chronic Hepatitis B; WHO: World Health 
Organization; HBV: Hepatitis B Virus; HCC: Hepatocellular Carci-
noma; HBsAg: Hepatitis B Surface Antigen; MALT: Mucosa-Asso-
ciated Lymphoid Tissue; GALT: Gut-Associated Lymphoid Tissue
Introduction
Chronic hepatitis B (CHB) still remains a major problem of 
health concern due to its significant morbidity and mortalitiy. 
According to the World Health Organization (WHO), nearly 240 
million people are chronically infected worldwide with hepatitis 
B virus (HBV) even though the availability of a hepatitis B vaccine 
placed in the market for more than 30 years [1]. 
HBV causes almost 50% of the world´s cases of hepatocellular 
carcinoma (HCC) and about 30% of all cases of liver cirrhosis [2], 
leading to over 780,000 annual deaths [3]. 
Considerable progress has been made in the last 20 years in the 
construction and development of effective prophylactic hepatitis 
B vaccines and in the implementation of childhood immunization 
programs so as to protect future generations. However, several 
gaps remain to be solved. Firstly, current hepatitis B vaccines 
induced a systemic immune response with a poor mucosal 
immunity and require a regimen of at least three intramuscular 
injections [4-6]. Secondly, the global coverage of a three-dose 
hepatitis B vaccine is 85-90%, that is, current vaccines have a 
10-15% of poor or non-responders rate [7]. This inadequate 
HBV vaccination coverage rates, especially in certain high-risk 
populations represents one of the most important unmet needs 
in the marketplace. Thirstly, the implementation of hepatitis 
B vaccination is still considerably low where it is most needed, 
especially in those low-income countries, such as Central Africa 
where the prevalence rates of HBV infection are too high [8,9]. 
This issue is secondary to the three dose vaccination schedule, the 
requirement of cold storage and the availability of sterile needles 
[10]. Finally, some of the vaccinated infants still sometimes get 
infected due to vaccine-escape mutants [11,12]. 
While the cure for CHB still appears a longer term alternative, 
the immediate and middle term challenges reside in the design 
of advanced vaccine formulations with improved release features 
of the immunogen and an improved stimulation of both cellular 
and humoral immune responses. Progresses have been made 
in specific areas such as Nanotechnology but this is certainly 
not enough. Scientists in technological fields in general and 
nanotechnologies in particular, are tacitly compromised with 
the challenges standing ahead. The present review describes the 
main drawbacks of the current available prophylactic hepatitis 
B vaccines and the state-of-the art of all the nanotechnological 
approaches reported until now with the aim of improving the host 
immune response after immunization as well as for optimized and 
long lasting protection and for overcoming the limiting aspects of 
these current hepatitis B vaccines.
Discussion
Hepatitis B vaccines history
In 1970, the plasma from an individual chronically infected 
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with HBV was inactivated by heat, diluted 1/10 and inoculated in 
healthy individuals. Thus, this plasma lost the infective but not the 
immunogenic properties of HBV, causing no disease in the healthy 
receptors that received it. In addition, these vaccinated receptors 
turned out to be protected against subsequent challenges with 
HBV. These purified native forms of the hepatitis B surface antigen 
(HBsAg) - the primary target of HBV-neutralizing antibodies- 
constituted the first evidence that led to the subsequent 
development of a vaccine obtained by plasmapheresis from 
human chronic carriers of HBV [13]. In 1981, as a result of the 
work conducted by Wolf Szmuness, the first vaccine against 
hepatitis B for widespread human use was licensed in the United 
States of America. This vaccine is now identified as the “first 
generation” hepatitis B vaccine. This vaccine has now been 
replaced by recombinant vaccines that are free of any concerns 
associated with human blood products [13].
Since 1986, recombinant vaccines produced by genetic 
engineering have been also licensed as safe and effective against 
hepatitis B [13].
Both plasma-derived and recombinant vaccines have HBsAg 
as immunogen and stimulate the active synthesis of anti-HBs 
antibodies, thus conferring protective humoral immunity in 
vaccinated individuals. An antibody titer of ≥10 mIU per ml 
measured 1-3 months after the administration of the last dose of 
the primary vaccination series is considered a reliable marker of 
protection against infection [14]. 
Other potential HBV immunogens, such as pre-S1 and pre-S2 
were also evaluated for the development of both prophylactic 
and therapeutic vaccines. Table 1 shows some of the currently 
available hepatitis B vaccines around the world.
Regarding recombinant hepatitis B vaccines, two and third 
generation vaccines were licensed and placed in the market 
for widespread human use. In second generation vaccines, the 
HBsAg gene has been inserted into yeast and mammalian cells by 
means of appropriate expression vectors [15]. Antigen expressed 
in several genus and species of yeasts, including Saccharomyces 
cerevisiae (Recombivax-HBTM and Engerix-BTM), Pichia pastoris 
(Enivac-HB, Shanvac B) and Hansenula polymorpha (ButanNG, 
GeneVac-B) has been used to produce hepatitis B vaccines for 
over 20 years [Table 1]. Recombinant HBsAg differs from its 
native counterpart only in the glycosylation of the protein, which 
can vary according to the production cell [16]. 
Table 1: Some of the currently available hepatitis B vaccines around the world.
Name Type Vaccine Company
Engerix B Recombinant HBV, HBsAg -2nd generation GlaxoSmithKline Biologicals
Recombivax HB Recombinant HBV, HBsAg- 2nd generation Merck & Co, Inc
ButanNG Recombinant HBV, HBsAg -2nd generation Butantan - Brazil
GeneVac-B Recombinant HBV, HBsAg -2nd generation Serum Institute of India- India
Bimmugen Recombinant HBV, HBsAg -2nd generation Kaketsuken - Japan
Vecon Recombinant HBV, HBsAg -2nd generation Biokangtai - China
Regevac B Recombinant HBV, HBsAg -2nd generation Binnopharm - Russia
Enivac-HB Recombinant HBV, HBsAg -2nd generation Panacea Biotec-India
Shanvac B Recombinant HBV, HBsAg -2nd generation Shantha-India
Bilive Hepatitis A and Hepatitis B - Bivalent Sinovac - China
TwinRix Hepatitis A and Hepatitis B - Bivalent GlaxoSmithKline Biologicals
Comvax Haemophilus b Conjugate Vaccine (Meningococcal Conjugate) and Hepatitis B - Bivalent Merck & Co, Inc
Pediarix Diphtheria, Tetanus, Pertussis,  Hepatitis-B and Hib – Pentavalent GlaxoSmithKline Biologicals
Pentaxim Diphtheria, Tetanus, Pertussis,  Hepatitis-B and Hib - Pentavalent Sanofi Pasteur MSD
Quinvaxem Diphtheria, Tetanus, Pertussis,  Hepatitis-B and Hib – Pentavalent Novartis AG
Easyfive-TT Diphtheria, Tetanus, Pertussis,  Hepatitis-B and Hib - Pentavalent Panacea Biotec – India
HEXYON Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus influenzae type b disease (Hib) - Hexavalent Sanofi Pasteur MSD
GenHevacB HBsAg and PreS2 - 3rd generation Institut Pasteur-France
Sci-B-Vac HBsAg, preS1 and PreS2 - 3rd generation SciVac Ltd – Israel
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Only two 3rd generation vaccines are commercially currently 
available: GenHevacB and Sci-B-Vac. The first one comprises the 
viral envelope proteins, HBsAg and pre-S2 whereas the remaining 
one comprises the three HBV envelope proteins: HBsAg, pre-S2 
and pre-S1. Both of them are produced in Chinese hamster ovary 
(CHO) cells. The active component is highly similar to the native 
counterpart, and it is more potent and immunogenic than the 
recombinant HBsAg used as immunogen in the existing yeast 
derived hepatitis B vaccines.
As in the first generation vaccines, the use of 2nd and 3rd 
generation vaccines in children and young people promotes the 
seroconversion to 85-90% of individuals. 
Hepatitis B vaccines global market
The global market for vaccines comprises about 2% to 3% of 
the total pharmaceutical market. Nevertheless, this sector has a 
high growth rate of 10% to 15% per year versus the 5% to 7% 
seen in the overall market. Currently, the global vaccine market 
has an estimated value of almost $24 billion and is projected to 
rise to $100 billion by 2025 [17].
More than 120 new products are in the development pipeline. 
Half of them - which account for less than 20% of the global market 
- are of great importance for the developing countries, since they 
comprise the 80% of the worldwide population. The main global 
vaccine players are Glaxo Smithkline, Sanofi Pasteur, Pfizer, Merck 
and Novartis. These 5 large multinational corporations make up 
80% of the global market. 
In this context the global hepatitis B vaccine market has an 
estimated value of $1.02 billion and will experience a modest 
growth over the coming years reaching $1.19 billion by 2022, at 
an annual growth rate of 2.2% [18].
The eight major markets (US, Canada, France, Germany, Italy, 
Spain, the UK and Japan) account for more than 55% of the global 
market and is estimated to reach more than 62% in the first years 
of the next decade (2020). 
The moderate growth in HBV vaccine sales will result from 
the launch of Dynavax Technologies’ Heplisav-B and the recently 
approved (2013) Sanofi Pasteur MSD’s Hexyon, with peak-
year sales anticipated to reach $85 million and $520 million, 
respectively.
Heplisav-B is an adult hepatitis B vaccine in Phase 3 
development that utilizes a proprietary TLR9 agonist to elicit a 
focused immune response providing improved protection against 
hepatitis B. The ongoing Phase 3 study is designed to provide a 
sufficiently-sized safety database for the FDA to complete its 
review of Dynavax’s biologics license application.
Hexyon is the first and only fully liquid pediatric hexavalent 
vaccine, ready-to-use, to protect infants against hepatitis 
B, diphtheria, tetanus, pertussis, poliomyelitis and invasive 
infections caused by Haemophilus influenzae type b.
Which are the most common drawbacks of hepatitis B 
vaccines?
The stricking non-responders rate(10-15%) together with 
the fact that current vaccines require a regimen of at least three 
intramuscular injections, a guaranteed cold chain from point of 
manufacture to point of use cold, and the availability of sterile 
needles, significantly increases the costs and limits the compliance 
of many low-income countries in the vaccination programs [7]. 
Furthermore, the currently prophylactic hepatitis B vaccines 
available in the market produce mainly a systemic immune 
response with an insignificant mucosal immune response [19]. 
In this regards, it is widely known that HBV is transmitted by 
parenteral or permucosal exposure, that is, HBV is considered a 
mucosal infection. Thus, there is a need to induce a significant 
long lasting and optimized mucosal immunity. 
Prevention of hepatitis B, one of the most prevalent human 
diseases, requires cheaper and more accessible vaccines. In 
addition, less invasive strategies and easier storage and transport 
requirements should also be prioritized. At present, scientists in 
technological fields in general and nanotechnologies in particular 
aim to find new technologies that contribute to the accessibility 
of all kinds of vaccines at lower costs, thus mainly benefiting the 
underserved populations. Several lines of research are arduously 
working to generate a new applicable, cheaper and translatable 
vaccine against hepatitis B using nanotechnology, as it is exposed 
below. In the following section, we will also gain insight into 
fundamental aspects related to mucosal immunization using 
nanotechnology. 
Nanodelivery systems for hepatitis B vaccines
An important issue is the mucosal immunization, an attractive 
alternative to parenteral vaccines because it offers an opportunity 
to stimulate both systemic and mucosal immune responses 
and avoids the need for sterile needles. It is widely known that 
parenteral vaccines does not usually offer an optimal or long 
lasting protection against diseases caused by microorganisms 
that are specially inhaled, ingested or sexually transmitted [19]. 
Hence, for optimal mucosal protection, induction of immune 
response via mucosal routes is desirably and thus mucosal 
vaccines emerge as a new promise and challenge for improving 
the efficacy of immunization. At present, there are a few mucosal 
vaccines approved by FDA such as RotaTeq (Merck - Rotavirus 
vaccine, a live attenuated oral vaccine), Rotarix (GlaxoSmithKline, 
a live oral attenuated vaccine), Adenovirus type 4 and type 7 
vaccine (Teva Pharmaceuticals, a live attenuated oral vaccine) 
and oral Polio vaccine (GlaxoSmithKline - a live attenuated oral 
vaccine made from Sabin strains). These are affective because 
they use live attenuated viruses. It is well known that a prolonged 
exposure of the immune system to the attenuated agent results 
in an increased immunogenicity and a long lasting immunity in 
comparison with traditional injectable counterparts (e.g. oral 
Polio vaccine versus injectable Polio vaccine, developed by Jonas 
Salk). However, risk of reversion to virulence makes attenuated 
vaccines undesirable for immunocompromised individuals and 
pregnant women. Other mucosal vaccines approved by FDA for 
human use are the oral typhoid fever vaccine (Vivotif Berna, 
Crucell Switzerlan LTD, a live attenuated strain of Salmonella typhi 
-Ty21a-), and the intranasal vaccine against influenza disease 
(FluMist Quadrivalent, AstraZeneca group, a live attenuated 
Influenza virus types A and B vaccine). As it is shown, all these 
mucosal vaccines are made of live attenuated microorganisms.
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Nanotechnology platforms have been employed for newly 
vaccine developments. It was reported that nanocarrier-based 
delivery systems may stimulate both humoral and cellular 
immune responses due to the nanoscale particle size [20]. The 
nanoparticles do not exceed 1,000 nm, leading this attribution 
to an easier uptake by phagocytic cells, antigen presenting 
cells, the mucosa-associated lymphoid tissue or MALT and 
the gut-associated lymphoid tissue or GALT which secrete the 
cytokine TGF-β, which induces IgA secretion [20]. This means, 
that these nanoparticles facilitates the antigen recognition and 
presentation, mainly through the specialized epithelial cells 
known as microfold M cells, which take up and transport antigens 
across the epithelial membrane to macrophages, dendritic cells 
and B and T cells present in the Peyer´s patches in the intestinal 
tract or in the nasal-associated lymphoreticular tissue of the 
oropharyngeal, the tonsils and adenoids in order to initiate 
and activate immune respone to the intact antigen [21,22]. 
Thus M cells remain good targets for mucosal vaccine-delivery 
systems. Hence, Nanotechnology is an important tool with the 
potential of improving or modulating the immunogenicity of a 
vaccine formulation. It is considered that an ideal nanodelivery 
system should have the ability to stimulate humoral, cellular and 
mucosal immune responses [23]. Many nanocarriers have been 
designed and investigated for their usefulness in the delivery of 
immunogens and adjuvants to immune cells so as to promote a 
protective immune response [24,25]. Among them, the most 
frequently reported as vaccines delivery systems are liposomes, 
nanoemulsions, nanospheres and polymer-based nanoparticles. 
The FDA approved a wide range of synthetic and natural polymers 
for the production of nano/microparticles to prepare controlled-
release delivery systems (Decapeptyl®, Lupron Depot®, Nutropin 
Depot®, Zoladex®, etc). 
In this context, and regarding new nanotechnological 
strategies for improving the efficacy of hepatitis B vaccine, Saraf 
et al incorporated HBsAg in lipid microparticles for mucosal 
immunization against hepatitis B [19]. These lipid particles 
had their own adjuvant effect for immunization via respiratory 
tract inducing immune responses at both systemic and mucosal 
sites. For the preparation of these lipid particles containing 
HBsAg, authors used a double emulsion-solvent evaporation 
(w/o/w) method. This formulation was stable, immunogenic 
and cellular uptake was efficiently achieved by systemic and 
alveolar macrophages. Considerable immune responses were 
also produced by the developed system due to MALT induction 
[19]. Makidson et al carried out a pre-clinical evaluation of a 
novel nanoemulsion-based hepatitis B mucosal vaccine using a 
nanoemulsion manufactured by emulsification of cetyl pyridinium 
chloride, Tween 80 (5%) and ethanol (8%) in water with soybean 
oil (64%) using a high speed emulsifier [24]. Results demonstrated 
that this formulation was safe and effective as a potential hepatitis 
B vaccine, and that it induced a Th1 associated cellular immunity 
to adequately control viral replication, a potential benefit as a 
therapeutic vaccine for CHB patients [26].
Jaganathan & Vyas [27] developed surface-modified DL-
lactide/glycolide copolymer (PLGA) microspheres with chitosan 
for nasal immunization using recombinant HBsAg [27]. These 
modified PLGA microspheres (cationic microspheres) produced 
humoral (both systemic and mucosal) and cellular immune 
responses upon nasal administration [27].
PLGA nanoparticles were also used for loading HBsAg, 
stabilizing this immunogen by co-encapsulation of trehalose 
and Mg(OH)2. The Ulex europaeus 1 lectin was anchored on the 
surface of these nanoparticles to target them to M-cells of the 
intestinal peyer´s patches as a strategy for oral immunization 
against hepatitis B [26]. Authors proposed that these lectinized 
nanoparticles could be a promising carrier-adjuvant for the 
targeted oral-mucosal immunization [28]. Other strategies to 
prevent degradation and increase the absorption of administered 
antigen, is its inclusion into biodegradable microspheres or 
liposomes or their expression in bacterial or viral vectors and 
plants [29,30].
Delivery systems containing monophosphoril lipid A (MLP) 
combined with aluminum salts or the saponin adjuvant Quil 
A have been developed and demonstrated to enhance both 
humoral and TH1 immune responses [23]. Calcium phosphate 
nanoparticles generated by mixing and stirring calcium chloride, 
sodium phosphate and sodium citrate were used in clinical trials, 
and demonstrated to be safe and to have an increased or even 
similar immune response to that achieved using aluminum salts 
[23]. They also displayed a mucosal immunity protection [23]. 
Another interesting work, showed that for the intranasal 
delivery of HBsAg, recombinant haemagglutinin (HA) protein 
from the Influenza virus was complexed with liposomes loaded 
with HBsAg. HA offered a better adherence of the immunogen to 
the mucosal surface than pristine liposomes [31]. When systemic 
and mucosal antigen titers were measured after immunization, 
results demonstrated that anti-HBsAg IgG titers were higher in 
HA-liposomes than in the pristine counterparts, but lower than 
alum vaccines administered intramuscularly. Secretory IgA in 
mucosal fluids were measured after 6 weeks of immunization 
showing higher titers using the liposomal complexes, especially 
those recovered on the surface with the HA protein, whereas in 
the case of the alum-HBsAg administered intramuscularly, titers 
rendered not legible. Through the measurement of the cytokines 
profile, it was observed that the Th1 response was dominant when 
the formulation HA-liposomes were administrated intranasally 
[31].
Tafaghodi et al used trimethylated chitosan and chitosan 
nanoparticles loaded with HBsAg for nasal immunizaton in 
a murine model [32] and results demonstrated that these 
nanoparticles may be promising for mucosal immunization. 
Chitosan is a natural copolymer with the ability to induce both 
humoral and cellular responses and even of producing Il-2 and 
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IFN-Ɣ, indicative of a Th1 response. Borges et al, used a similar 
immunization system with HBsAg encapsulated into alginate-
coated chitosan nanoparticles, and similar results they achieved. 
Authors also reported that the cellular responses they measured 
were accompanied with anti-HBsAg.specific IgG in the sera and 
IgA in the intestinal mucosa [33].
A novel adaptated version of the liposome/niosome system 
is the development of bilosomes, which are non-ionic surfactant 
vesicles-based systems with bile salts. This nanotechnological 
platform displayed a high stability after oral administration of an 
immunogen, and also induces significant antibody titers. These 
formulations are so stable, that the need for “cold chain” supply 
is no necessary [21]. 
In summary, the expected advancements obtained using all 
these nanotechnological platforms are administration regimes 
less frequent, more compliant vaccination programs, lower costs, 
optimal mucosal protection, an enhanced humoral and cellular 
immune response and less stringent cold requirement due to a 
higher stability [34]. These issues are highly relevant mainly in 
low-incoming countries with high HBV endemicity. Moreover, 
these achievements may extend their applicability to other 
vaccines. 
Conclusion
Nanotechnology has contributed to improve the administration 
and delivery of many drugs and immunogens. A press release by 
Cientifica Ltd. foresees a critical expansion in the nano-based drug 
delivery market from its current $3.4 billion (10% of the total drug 
delivery market) to about $220 billion in 2015. Regardless the 
apparently difficult implementation, a number of reasons support 
the fact that nanotechnologies can provide unique solutions also 
in poorer societies, such as many areas of Africa, Asia and South 
America:
i. Strong nanotechnology research in developing countries 
oriented to solve specific prophylactic and therapeutic pro-
blems of their own communities will make these new techno-
logies more affordable. Programs like the Horizon 2020 make 
possible this kind of initiatives.
ii. Increasing funding by public and private organizations for re-
search on specific diseases affecting primarily the developing 
world; e.g. the Global Alliance for Vaccine and Immunization 
(the GAVI Alliance) and the Hepatitis B Foundation together 
with the Centers for Disease Control and Prevention, the Ame-
rican Liver Foundation and the Pennsylvania Department of 
Health among other partnerships is stimulating research on 
everything related to hepatitis B and additional funding is be-
ing devoted. 
iii. Nanotechnology-related mucosal immunization may impro-
ve the prophylactic success by stimulating both humoral and 
cell-mediated responses, inducing mucosal and systemic im-
munity simultaneously, doing administration regimes less fre-
quent, vaccination strategies more compliant and needle free 
and attaining higher responding rates and altogether reducing 
substantially the vaccine regimens costs. Moreover, they can 
enhance the effectiveness of approved vaccines and extend 
their applicability to other ones by providing means to overco-
me the current drawbacks, such as high costs, the requirement 
for cold storage and the availability of sterile needles. 
iv. Commitment between pharmaceutical companies and gover-
nments, international agencies to make prices of new vaccines 
and technologies more affordable. 
Finally, to design and implement nanotechnologies at 
reasonable costs and to make them affordable to people in 
developing countries are key ethical and scientific challenges. 
This would probably make possible transforming a certainly 
chronic and even fatal disease into a highly preventable one, for 
all the patients regardless their socioeconomic status. This is a 
main endeavour of many researchers and the main message of 
the present work. 
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